Innovassynth Technologies Board Approves ₹70 Crore Rights Issue
Innovassynth Technologies (India) Limited's board has approved a rights issue to raise up to ₹70 crores through equity shares with face value of ₹10 each. The board constituted a Rights Issue Committee to determine key terms including issue size, entitlement ratio, pricing, and timing, with the record date to be announced later subject to regulatory approvals.

*this image is generated using AI for illustrative purposes only.
Innovassynth Technologies (India) Limited's board of directors has approved a rights issue proposal to raise funds up to ₹70 crores through equity shares. The board meeting held on March 27, 2026, concluded with the approval of issuing equity shares of face value ₹10 each to eligible shareholders.
Board Meeting Outcome
The board meeting, which commenced at 4:30 p.m. and concluded at 4:50 p.m., addressed the fund-raising proposal and approved the rights issue for an aggregate amount not exceeding ₹70 crores, subject to receiving applicable regulatory and statutory approvals. The company formally notified BSE Limited about the board meeting outcome pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
| Rights Issue Details: | Specifications |
|---|---|
| Maximum Amount: | ₹70,00,00,000 (Seventy Crores) |
| Share Face Value: | ₹10 per equity share |
| Issue Type: | Rights Issue to eligible shareholders |
| Record Date: | To be notified subsequently |
| Meeting Duration: | 4:30 p.m. to 4:50 p.m. |
Rights Issue Committee Formation
The board constituted a dedicated Rights Issue Committee with authorization to determine crucial aspects of the offering. The committee will decide on terms and conditions including the final issue size, rights entitlement ratio, issue price, record date, timing of the rights issue, approval of draft letter of offer, allotment of shares and other related matters.
| Committee Responsibilities: | Details |
|---|---|
| Issue Size: | Final amount within ₹70 crore limit |
| Entitlement Ratio: | Rights shares per existing share |
| Pricing: | Issue price determination |
| Documentation: | Draft letter of offer approval |
| Allotment: | Share allotment and related matters |
Regulatory Compliance and Documentation
The company's communication to BSE was signed by Sameer Pakhali, Company Secretary (ACS 55746), and digitally authenticated on March 27, 2026. The filing included detailed annexure as required under Regulation 30 of the Listing Regulations read with SEBI circular SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.
| Regulatory Details: | Information |
|---|---|
| Security Type: | Equity Shares |
| Issuance Type: | Rights Issue |
| BSE Scrip Code: | 533315 |
| Company Secretary: | Sameer Pakhali (ACS 55746) |
| Authentication Date: | March 27, 2026 |
Company Information
Innovassynth Technologies (India) Limited operates from its registered office at Old Mumbai–Pune Road, Khopoli – 410 203, and corporate office at TCG International Biotech Park, 2nd Floor, Genesis Square, Hinjewadi Phase – II, Pune – 411 057. The company trades on BSE under scrip code 533315 with CIN: L67120MH2008PLC178923. The rights issue represents a significant capital mobilization initiative for the company's growth plans.
Historical Stock Returns for Innovassynth Technologies
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.76% | +10.94% | -1.45% | -18.73% | -5.92% | +1,123.14% |
What specific growth initiatives or expansion plans will Innovassynth fund with the ₹70 crore capital raise?
How might the rights issue pricing and entitlement ratio affect existing shareholder dilution and market reception?
Will this capital infusion enable Innovassynth to compete more effectively in India's biotechnology sector against larger rivals?































